Evercore ISI analyst Daniel Markowitz had a “Tactical Outperform” call on West Pharmaceutical (WST) heading into earnings, but is removing it from the firm’s TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $325 from $275 at Barclays
- West Pharmaceutical price target raised to $370 from $310 at BofA
- West Pharmaceutical price target raised to $355 from $320 at UBS
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
- West Pharmaceutical Services Reports Strong Q3 2025 Results